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This project investigates the 3D molecular modeling of hyaluronic acid (HA), 
curcumin, polylactic-co-glycolic acid (PLGA) and polyethylene glycol bis amine 
(PEG-bis amine) and all the possible conjugated forms between the compounds as 
bioconjugates for targeted delivery to cancer cells. Modeling work had been done 
using Discovery Studios 2.5 from Accelrys Inc. USA. The study focuses on targeted 
delivery of curcumin to colorectal cancer cells. The generated model will be used in 
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1.1 BACKGROUND OF STUDY 
Cancer is one of the major diseases that cause 13% of all human deaths in 2007 
(Gul-e-Saba et al., 201 0). Cancer is a result of rapid growth of normal cells, which 
can harm human body (Pal & Nayak, 20 10). Drugs such as cisplatin, doxorubicin 
have been developed for chemotherapy but most have side effects towards particular 
tissues or cells which are not the cancer cells or tumors. Curcumin, a natural 
polyphenolic compound, has shown promising chemopreventive and 
chemotherapeutic activities in cancer (Yallapu, et al., 2010) but couldn't achieve its 
optimum therapeutic outcome in the past clinical trials, largely due to its low 
solubility and poor bioavailability (Basnet & Basnet, 2011). Targeted drug delivery 
to cancer cells is of utmost important to selectively target diseased tissue while 
leaving healthy tissue untouched (Sutton et al., 2007). Hyaluronan (HA) is a major 
component of extracellular matrix (ECM) and main ligand of CD44 receptor cells 
(Gul-e-Saba, et al., 2010). HA-CD44 binding will play major role in development of 
targeted control drug delivery to cancer cells. One of the advanced tools that could 
help drug developers is the computational modeling for designing, testing and 
simulating the molecular structure of the drugs. The need for drug modeling assists 
better understanding of the interactions of the drug with microenvironment in the 
body at the disease sites. In this study, hyaluronic acid containing curcumin-loaded 
polylactic-co-glycolic acid bioconjugates as a potential anticancer drug will be 
modeled and discussed for targeted delivery. 
1.2 PROBLEM STATEMENT 
When any new type of drugs is to be used in human body, the process of design and 
development of drug will involve many trial and error experiments based on 
previous research. This method is time consuming, costly and fraught with 
uncertainties. Computational modeling to design the molecular structure to see the 
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behavior of a drug reacting once injected or consumed in human cells, is a rational 
approach in drug design and modification which is economical and saves time with 
limited risk of failures as far as screening for lead compounds is concerned and it is 
also reduce the limitations of potent anticancer agents. 
1.3 OBJECTIVES 
1.3.1 To model the molecular structure of Hyaluronic Acid (HA) containing 
curcumin-loaded PLGA bioconjugates by using Discovery Studio 2.5. 
1.3.2 To demonstrate the application of controlled, targeted drug delivery system 
based on 3D molecular model developed. 
1.4 SCOPE OF STUDY 
In this project, the 3D molecular structure of Hyaluronic Acid (HA) containing 
curcumin-loaded PLGA bioconjugates as potential anticancer drug for controlled, 
targeted delivery to cancer cell will be modeled using Discovery Studio 2.5 
(Accelrys Inc., USA). 
1.5 FEASIBILITY STUDY 
Discovery Studio 2.5 (Accelrys Inc., USA) is available in UTP computer lab for 
students to use at all time and together with the project itself involves the compounds 
that have been known its molecular structure, therefore computational modeling of 
them is possible to generate and complete within project timeframe. Drug design 
using computational modeling is one of the advanced tools yet that could help drug 





2.1 COLORECTAL CANCER 
Colorectal cancer is one of the most common tumors and a major cause of cancer 
death worldwide (Fiore et al., 2007). It is a disease in which malignant (cancer) cells 
form in the inner lining of the colon or rectum (Rex & Liangpunsakul, 2007). Fig. 
2.1 shows developmental phases of colorectal cancer. The risk is increased with low 
fiber intake, high fat diet, and low calcium/micronutrient intake (Johnson & 
Mukhtar, 2007). Epidemiologic studies have revealed a number of risk factors for 
colorectal cancer including age, family history of colon cancer or inflammatory 
bowel disease, smoking, alcohol consumption, obesity, and diet (Byrne, 2008). 
Regular colorectal cancer screening which is the process of looking for cancer or 
symptoms or pre-cancer in people who show no symptoms is one of the ways for 
preventing colorectal cancer. 
2.2 CURCUMIN AS ANTI-CANCER COMPOUND 
Curcumin [(IE,6E)-I, 7 -bis( 4-hydroxy-3-methoxyphenyl)-1 ,6-heptadiene-3,5-dione] 
is a natural extract from Curcuma longa herb or normally known as turmeric (Fig. 
2.2) commonly used in India and Eastern Asia. It is an orange-yellow, crystalline 
powder with melting point of l83'C, molecular formula ofC21H2o06 and molecular 
weight of 368.37 g/mol (Lin & Lin, 2008). There are three major curcuminoids in 
turmeric, namely curcumin (diferuloylmethane), demethoxycurcumin, and 
bisdemethoxycurcumin (Fig. 2.3) (Basnet & Basnet, 20 ll ). Curcumin has shown 
anti-inflammatory and anti-cancer properties (Sharma et al., 2005), highly 
hydrophobic agent (Anand et al., 2007), prevent the transformation, proliferation, 
and invasion of tumor cells (Shishodia et al., 2007). Turmeric is Generally 
Recognized As Safe (GRAS) by the US FDA, and curcumin has been granted an 
acceptable daily intake level of 0.1-3 mglkg-BW by the Joint FAO/WHO Expert 
Committee o Food Additives, 1996 (Institute, 1996). Based on the safety and toxicity 
profile in several clinical studies shows that the targeted doses for curcumin can be 
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recommended in between 4,000-8,000 mg to obtain the maximum therapeutic effects 
(Basnet & Basnet, 2011). The only factor that limits the use of free curcumin for 
cancer therapy is its poor solubility in water, which in tum limits its systemic 
bioavailability when administered orally (Dinarvand, et al., 2011 ). Utilization of 
nanotechnology has proven to be very effective in solving this problem (Bharali , et 
al. , 20 II). Some studies demonstrated that curcumin encapsulation in PLGA 
nanoparticles produced a very stable nanoformulation and also enhanced cellular 
drug uptake and retention, as well as sustained release of curcumin (Dinarvand, et 
al., 20 II). 
Anti-cancer agent refers to a compound capable of negatively affecting cancer in a 
subject, for example, by killing, inducing apoptosis, reducing the growth rate of one 
or more cancer cells, reducing the incidence or number of metastases, reducing a 
tumor's size, inhibiting a tumor' s growth, reducing the blood supply to a tumor or 
one or more cancer cells, promoting an immune response against one or more cancer 
cells or a tumor, preventing or inhibiting the progression of a cancer, or increasing 
the lifespan of a subject with a cancer (Kiostergaard, et al., 20 I 0). 
Figure 2.1 Developmental phases of colo rectal cancer (QIAGEN, 20 II). 
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Figure 2.2 Curcuma longa (Duvoix et al., 2005). 
0 0 
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Figure 2.3 Fractions oftunneric known as curcuminoids (curcumjn, demethoxycurcumin, 
and bisdemethoxycurcumin) (Basnet & Basnet, 2011). 
2.3 PLGA AS A DRUG-DELIVERY AGENT 
Drug-delivery agent or drug-carrier nanoparticles are defined as submicroscopic 
colloidal systems that may act as drug vehicles, either as nanospheres (matrix system 
in which the drug is dispersed) or nanocapsules (reservoirs in which the drug is 
confined in a hydrophobic or hydrophilic core surrounded by a single polymeric 
membrane) (Jeanneret, 2008). Figure 2.4 shows two major loading models-
Liposome and Micelle-for effectively loading water soluble and water insoluble 
natural chemopreventive agents, respectively (Muqbil, et al., 20 I I). Figure 2.6 
shows how nanoparticles do interact with immune system; a) The effect of 
nanoparticle size, charge, hydrophobicity and targeting or immunotoxicity and b) 
Some nanoparticles (shown schematically) can trigger certain immune responses as 
listed there, a characterization scheme for nanoparticles intended for biomedical 
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applications must include testing for these responses, such tests may exclude a 
potentially harmful drug candidate from the development pipeline and infonn future 
studies relevant to the immunomodulatory properties of nanoparticles 
(Dobrovolskaia & McNeil, 2007). 
Polylactic-co-glycolic acid (PLGA) has been developed to be one of the carrier 
molecules for targeted delivery of the anticancer drug (Yadav et at., 2010). It is one 
of the most studied diblock copolymer biomaterials for drug encapsulation and is 
present in several commercially available pharmaceutical products (Mansour et at., 
201 0). Schematic representation of PLGA molecular structure is shown in Fig. 2.5. 
In a study to test for the quality of the curcumin-loaded PLGA nanospheres as 
potential anticancer drug, PLGA grade of Poly(D,L-Iactide-co-glycolide) 50:50 has 
been used, having inherent viscosity 1.13 dl/g and MW 50000 (Mukerjee & 
Vishwanatha, 2009). A unified atomic mass unit of PLGA of 40-75KDa has been 
reported (Yadav et at., 2010). Studies have shown the possibility of having PLGA 
nano-fonnulation of curcumin as anticancer agent (Basnet & Basnet, 20 I I). 
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Figure 2.6 Nanoparticle properties detennine their interaction with the immune system 
(Dobrovolskaia & McNeil, 2007). 
2.4 HYALURONIC ACID CONTAINING BIOCONJUGATES 
Hyaluronic acid (HA) is a repeating disaccharide units composed of 0-glucuronic 
acid and N-acetyl-0-glucosamine and can be considered as the main component of 
the extracellular matrix of the cell membrane. It plays an important role in the 
mechanical support of the cell of many tissues, such as skin, tendons, muscles and 
cartilage (Mohapatra et at., 2008). HA can interact with CD44, its receptor at the cell 
surface which can lead to the site-specific delivery or targeted delivery of drug 
(Yadav et at., 20 I 0), which later on degraded inside the cells (Luo et at., 2009). 
Nanoparticles composed of HA, can be encapsulated and formulated with various 
peptide, DNA and drugs (curcumin) for cell specific drug delivery. The 
nanoparticles are natural polymers, biocompatibles and biodegradables such as 
PLGA. PLGA allows controlled release of the active molecules such as anti-cancer 
drug and their orientation towards the target tissues (Mohapatra et at., 2008). 
Targeting anti-cancer agents to tumor cells and tumor metastases can be 
accomplished by receptor-mediated uptake of bioconjugates such as anti-cancer 
agents conjugated to HA, followed by the release of free drugs through the 
degradation of HA in cell compartments (Luo et al., 2009). Fig. 2. 7 shows the 
structure of HA-curcumin conjugates and Fig. 2.8 shows CD-44 receptor on cell 
membrane. 
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Figure 2.7 Structure of hyaluronic acid (HA}-curcumin conjugate. 
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Figure 2.8 Schematic representation ofCD44 molecule (Gul-e-Saba et al., 2010). 
2.5 POL ¥ETHYLENE GLYCOL BIS AMINE AS CROSSLINKING AGENT 
Poly(ethylene glycol) (PEG), aJso known as polyethylene oxide (PEO), is a largely 
exploited polymer for advanced physical and chemical stability of drugs and its 
"stealth" properties (Mansour, et al., 20 I 0). When PEG is properly linked to a 
polypeptide, it modifies many of its features while the main biological functions, 
such as enzymatic activity or receptor recognition maybe maintained (Veronese, 
200 I). Addition of PEG or PEG-containing copolymers to the nanoparticle surface 
results in an increase of half-life in the blood circulation by several orders of 
magnitude (Dinarvand, et al., 20 I I). 
Polyethylene glycol-his amine (PEG-bis amine) is used as an intermediate in the 
synthesis of crosslinking agents for polymerization and surface modification of 
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hemoglobin or other proteins for pharmacological use (Hai, et al., 2003). A two step 
mechanism for the preparation of PEG-bis amine comprising a first step of reacting 
the terminal hydroxyl groups of PEG with a halogen substituted aromatic sulfonyl 
halide in a solvent to form a disubstituted sulfonyl activated polyethylene glycol 
intermediate and in a second step the intermediate is directly aminated with ammonia 
to give PEG-bis amine (Fig. 2.9) (Hai, et al., 2003). 




3.1 RESEARCH METHODOLOGY 
The study has been divided into 2 stages for molecular modeling as follows: 
3.1.1 Uni-molecular Modeling 
All of the following main molecules will be modeled separately using Discovery 
Studios 2.5 (Accelrys Inc., USA): 
3.1.1.1 An anticancer agent (curcumin) 
3.1.1.2 A carrier molecule (PLGA) 
3.1.1.3 Hyaluronic acid (HA) 
3.1.1.4 Spacer Arm (PEG-bis amine) 
3.1.2 Multi-molecular Modeling 






3.2 PROJECT ACTIVITIES 
The following shows the instruction of molecular modeling for each of the molecules 
according to previous session which will be described in details using Discovery 
Studios 2.5 (Accelrys Inc., USA). 
The molecular modeling has been divided into 2 stages: 
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3.2.1 Uni-molecular Modeling 
All of the following main molecules had been modeled separately using Discovery 
Studios 2.5 (Accelrys Inc., USA) together with their instruction step-by-step for each 
of the modeled molecule: 
3.2.1.1 An anticancer agent (curcumin) 
The study chose curcumin I to be modeled (refer to Fig.2.3) and the following shows 
its modeling instruction: 
I) Discovery Studios 2.5 was opened by using its software icon on the 
desktop. 
2) Molecule window was opened from menu File I New I Molecule 
Window. 
3) The Ring Tool was selected from Sketching Toolbar. 
4) The 2 rings with 6 carbon atoms each was created by clicking in 
molecular window for 2 times on left and right of the screen. 
5) The Draw Tool was selected from Sketching Toolbar. 
6) For the I st ring on the left of the screen, the lower left atom was clicked 
then the mouse was dragged to lower left and single click was pressed 
after that to make a new atom and by clicking on the new atom, it 
released the cursor. Then, the upper left atom of the ring was clicked and 
the mouse was dragged to upper left side with single clicking to make I 
atom and one more clicking to the left to add another I atom. The cursor 
was released by clicking on the new atom just added. Since both of the l't 
atoms added and attached to the ring is oxygen atom so that changing of 
the atom was needed. This was successfully done by choosing Select 
Tool from View Toolbar then right mouse button was clicked to show the 
pull-down menu then option Element > 0 was selected for both of the 
atoms. 
Note: Releasing the cursor can be done also by dragging the mouse out of 
document window. 
7) For the 2"d ring on the right of the screen, the lower right atom was 
clicked then the mouse was dragged to lower right and single click was 
11 
pressed after that to make a new atom and by clicking on the new atom, it 
released the cursor. Then, the upper right atom of the ring was clicked 
and the mouse was dragged to upper right side with single clicking to 
make 1 atom and one more clicking to the right to add another I atom. 
The cursor was released by clicking on the new atom just added. Since 
both of the 1st atoms added and attached to the ring is oxygen atom so 
that changing of the atom was needed. This was successfully done by the 
same method as previous step 6). 
8) The Chain Tool was selected from Sketching Toolbar. 
9) The upper right atom of the I st ring was clicked and the new atom 
appeared then it was clicked while holding the left mouse button down. 
The mouse was dragged across to make the side chain of totally 9 atoms; 
it was the number appearing to show the number of atom in the chain 
while dragging the mouse. 
1 0) The whole 2"d ring was selected using the Select Tool then the mouse was 
clicked and dragged to draw a region covering the whole 2"d ring and 
once it had been done, the selected ring will be highlighted with yellow 
color. Next, the whole 2"d ring was moved and placed nearby another side 
of the chain drew in previous step and by selecting Draw Tool, the atom 
of the chain at the end was clicked and then the link between this atom 
and the upper left comer atom of the 2"d ring was created by clicking on 
that atom on the ring. The cursor was released with the same method as 
previously mentioned. 
II) The single atom was added on the side chain at atom number 3 and 5 
using Draw Tool. These atoms were changed into oxygen atoms by the 
same method as mentioned before in step 6). 
12) The Select Tool was chose and all the single bonds that need to be 
converted to double bond had been selected. Then by pressing number 2 
on the keyboard or by clicking on Double Bond in Chemistry Toolbar, it 
automatically changed into double bond. 
l3)The Show Hydrogen was selected from Chemistry Toolbar. This made 
the hydrogen appeared on each of the atoms that available on the modeled 
structure. 
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14) Optimizing the geometry of the structure was needed since the drawing 
model was not yet precise and accurate in terms of standard bond length, 
bond angles and Van der Waals radii for close contact. The Clean 
Geometry was chose from Chemistry Toolbar; this can be clicked 
repeatedly until there's no longer changing in the model. 
15)Annotation to the model was needed by choosing Annotation Tool in 
Sketching Toolbar and left clicking on the place where to put the 
annotation then the word 'Curcumin' was typed in the dialog box and 
finally the 'OK' button was pressed. The completed model of curcumin 
has illustrated in the next chapter (Fig. 4.1 ). 
3.2.1.2 A carrier molecule (PLGA) 
The current study choose to model only some portion of PLGA molecular structure 
as shown in previous chapter (refer to Fig. 2.5). PLGA modeling instruction has 
been illustrated as follow: 
1) The Chain Tool was chosen from Sketching Toolbar to draw the chain 
total of 7 atoms. 
2) The single atom was added on the side chain at atom number 2, 3 and 5 
using Draw Tool. The atom added at number 2 and 5 were changed into 
oxygen atom together with atoms on the chain number I, 4 and 7 by the 
same method used in previous curcumin model. 
3) The Select Tool was chose and all the single bonds that need to be 
converted to double bond had been selected. Then by pressing number 2 
on the keyboard or by clicking on Double Bond in Chemistry Toolbar, it 
automatically changed into double bond. 
4) The Show Hydrogen was selected from Chemistry Toolbar. This made 
the hydrogen appeared on each of the atoms that available on the modeled 
structure. 
5) Optimizing the geometry of the structure was needed using the same 
method mentioned in previous model. 
6) The annotation of PLGA was added using the same method explained in 
curcumin model. The complete model structure of PLGA has been 
illustrated in the next chapter (Fig. 4.2). 
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3.2.1.3 Hyaluronic acid (HA) 
The modeling of HA refers to the structure in Fig. 2.7 and the following is its 
modeling instruction: 
1) The Ring Tool was selected from Sketching Toolbar in order to draw the 
two rings with the size of 6 atoms each. 
2) The Draw Tool was selected to add all the chain to both 2 rings. 
3) Some of the atoms have changed into oxygen atom and nitrogen atom by 
the same method used for curcumin. 
4) All the double bond had been located using Double Bond button in 
Chemistry Toolbar. 
5) The 2 rings had been connected using Draw Tool to draw the bond 
between these two structures at the atom according to Fig. 2. 7. 
6) The Show Hydrogen was selected from Chemistry Toolbar. This made 
the hydrogen appeared on each of the atoms that available on the modeled 
structure. 
7) The modeling of HA had been optimized by clicking on Clean Geometry 
button in Chemistry Toolbar until there's no changing in the model. 
8) The annotation of HA was added using the same method explained in 
curcumin model. The complete model structure of HA has been 
illustrated in the next chapter (Fig. 4.3). 
3.2.1.4 Spacer arm (PEG-bis amine) 
The modeling ofPEG-bis amine refers to the structure in Fig. 2.9 and the following 
is its modeling instruction: 
1) The Chain Tool was chosen from Sketching Toolbar to draw the chain 
total of 7 atoms. 
2) The Select Tool was chosen from View Toolbar then right mouse button 
was clicked on atom number I to show the pull-down menu then option 
Element > N was selected for nitrogen. The same procedure was done for 
atom number 7 as well but it was difference for atom number 4 which 
has been changed into oxygen atom. 
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3) The Show Hydrogen was selected from Chemistry Toolbar. This made 
the hydrogen appeared on each of the atoms that available on the 
modeled structure. 
4) The modeling of PEG had been optimized by clicking on Clean 
Geometry button in Chemistry Toolbar until there's no changing in the 
model. 
5) The annotation of PEG was added using the same method explained in 
curcumin model. The complete model structure of PEG has been 
illustrated in the next chapter (Fig. 4.4). 
3.2.2 Multi-molecular Modeling 
The following conjugates have been modeled using Discovery Studios 2.5 (Accelrys 
Inc., USA): 
3.2.2.1 PLGA-HA 
The structure of these conjugated molecules has shown in Fig. 3.1. 
.•. . ..
Figure 3.1 PLGA grafted HA copolymer (Lee, Ahn, & Park, 2009). 
The modeling structure of these conjugated molecule had been completed for only 
one HA molecule which is smaller than structure shown in Fig 3.1 which contains 
two HA molecules. The modeling instructions of these conjugated structure is 
simply take the uni-molecule that we have in previous modeling and make a link 
bond between these two molecules as illustrated in Fig. 3.1. The completed modeling 
of this conjugated structure will be shown in the next chapter (Fig. 4.5). 
3.2.2.2 Curcumin-HA 
This modeling structure refers to Fig. 2.7. The modeling instruction of curcumin 
conjugated HA had been done by taking those two uni-structures and then make a 
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link bond between them as illustrated in Fig. 2.7. Clean Geometry tool had used to 
optimize the conjugated molecule and the completed modeling structure will be 
shown in the next chapter (Fig. 4.6). 
3.2.2.3 PLGA-PEG-HA 
The structure of these conjugated molecules has shown in Fig. 3.2. 
[ 
"" 
Figure 3.2 Schematic representation of synthesis ofHA-PEG-PLGA polymer (Yadav, et al ., 2010). 
The modeling instruction ofHA-PEG-PLGA polymer had been done by taking those 
three uni-structures and then makes a link bond between them as illustrated in Fig. 
3.2. Clean Geometry tool had used to optimize the conjugated molecule and the 







Figure 3.3 Targeted PLGA nanoparticle carrying the chemotherapeutic drug (Dinarvand, et at., 20 I I) 
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This modeling structure refers to Fig. 2.4 and Fig. 3.3. The modeling instruction of 
curcumin-PLGA-PEG-HA had been done by taking one molecule of curcumin and 
those PLGA-PEG-HA polymers in previous result and then makes a spherical shape 
over curcumin by selecting the curcumin molecule and the option under Tools Tab 
which is 'Define and Edit Binding Site' category followed by selecting ' Create 
Sphere' . The spherical shape appeared covering curcumin inside. Then covering the 
sphere by selecting PLGA-PEG-HA polymer and copying it and pasting it at the 
surface of sphere but need to make sure that only PLGA molecule would touch the 
sphere as inner with the outer of HA molecule. The completed modeling structure 
will be shown in the next chapter (Fig. 4.8). 
3.3 TOOLS REQUIREMENT 
Tools requirement as for development of the molecular modeling are shown below. 
3.3. 1 Hardware 
• Computer 
3.3.2 Software 
• Discovery Studios 2.5 (Accelrys Inc., USA) 
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Figure 3.4 User interface of Discovery Studios 2.5 (Accelrys Inc., USA). 
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CHAPTER4 
RESULTS AND DISCUSSION 
4.1 MOLECULAR MODELING 
The following content illustrate the molecular modeling developed by using 
Discovery Studios 2.5 (Accelrys Inc., USA). 
4.1.1 Uni-molecular Modeling 




Figure 4.1 Molecular modeling of curcumin (with atom number). 
The modeling of curcumin has been shown in Fig. 4.1. The red atom indicates 
oxygen atom, the dark grey atom indicates carbon atom and the light grey atom 
indicates hydrogen atom. The bond length between each atom has also been 
calculated using function in the software together with its basic properties as shown 
in Table 4.1 and 4.2, respectively. 
Table 4.1 Bond and bond length of curcumin. 
No. Name Parat Order Type Lelld(A) 
I Cl- C2 Curcumin 2 Double 1.32923 
2 C2 -C3 Curcumin I Single 1.46169 
3 C3 -C4 Curcumin 2 Double 1.32782 
4 C4-C5 Curcumin I Single 1.4662 
5 C5-C6 Curcumin 2 Double 1.35625 
6 C6-CJ Curcumin I Single 1.47053 
7 C5 - 07 Curcumin I Single 1.39542 
8 C6-08 Curcumin I Single 1.45342 
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No. Name Parent· Order Type Length (A) 
9 C9-CIO Curcumin 2 Double l.334I2 
10 CIO- Cll Curcumin I Single 1.45658 
II Cll-Cl2 Curcumin . I Single 1.50271 
12 CI2- Cl3 Curcumin I Single 1.5026 
13 Cl3- Cl4 Curcumin I Single 1.45672 
I4 CI4- CI5 Curcumin 2 Double 1.33515 
I5 CIS- CI6 Curcumin I Single 1.48623 
16 C2-C9 Curcumin I Single 1.47967 
I7 Cll-OI7 Curcumin 2 Double 1.23582 
18 Cl3- OI8 Curcumin 2 Double 1.23587 
I9 CI9-C20 Curcumin 2 Double 1.33295 
20 C20- C21 Curcumin I Single 1.55536 
21 C2I- C22 Curcumin 2 Double l.3319I 
22 C22-C23 Curcumin I Single 1.45423 
23 CI6- Cl9 Curcumin I Single 1.4569I 
24 CI6- C23 Curcumin 2 Double 1.33304 
25 C20-024 Curcumin I Single 1.45352 
26 C21- 025 Curcumin I Single 1.42368 
27 024 -C26 Curcumin I Single I.41594 
28 08- C27 Curcumin I Single 1.43531 
29 CI- HI Cure urn in I Single 1.0602I 
30 C3-H2 Curcumin I Single 1.05826 
3I C4-H3 Curcumin I Single 1.06032 
32 07 -H4 Curcumin I Single 0.988694 
33 C9-H5 Curcumin I Single 1.06027 
34 CIO -H6 Curcumin I Single 1.05684 
35 CI2 -H7 Curcumin I Single 1.09892 
36 Cl2- H8 Curcumin I Single 1.0992 
37 CI4-H9 Curcumin I Single 1.057I6 
38 CI5 -HIO Curcumin I Single 1.06027 
39 Cl9- Hll Curcumin I Single 1.0602 
40 C22 -HI2 Curcumin I Single 1.0603 
4I C23 -Hl3 Curcumin I Single 1.05659 
42 025- HI4 Curcumin I Sin11;le 0.94I025 
43 C26- HI5 Curcumin I Single 1.0993 
44 C26-HI6 Curcumin I Single 1.09957 
45 C26-HI7 Curcumin I Single 1.09965 
46 C27- HIS Curcumin I Single 1.09929 
47 C27- HI9 Curcumin I Single 1.09989 
48 C27- H20 Curcumin I Single 1.09983 
The curcumin structure shows the total measurement of 48 bond length with average 
bond length of 1.266556 A. 
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Table 4.2 Basic properties of curcumin. 
Properties Caraa•ia 
Number of Atoms 47 
Molecular Formula C21 H20 06 
Molecular Composition C: 0.685, H: 0.055, 0: 0.261 
Molecular Weight 368.391 
Exact Molecular Weight 368.126 
Net Formal Charge 0 
According to Table 4.2, the exact molecular weight of curcumin is slightly lower 
than its molecular weight because exact molecular weight is the mass of a molecule 
calculated with only the most abundant isotopes present which are usually the 
lightest isotopes (University of Colorado, 2011). Since curcumin is the neutral 
molecule therefore the net formal charge is equal to zero. 




Figure 4.2 Molecular modeling ofPLGA (with atom number). 
The molecular modeling of PLGA has been demonstrated in Fig. 4.2. The color of 
atoms indicates the same element as in previous modeling. The bond length of 
PLGA and its basic properties has also been evaluated as appeared in Table 4.3 and 
4.4, respectively. 
Table 4.3 Bond and bond length of PLGA. 
No. Name Parellt Order Type ·~llfll(.t\) 
I 01 -C2 PLGA I Single 1.42944 
2 C2 -C3 PLGA 1 Single 1.50007 
3 C3 -04 PLGA I Single 1.40999 
4 04-C5 PLGA I Single 1.44509 
5 C5 -C6 PLGA 1 Single 1.5004 
6 C3 - 07 PLGA 2 Double 1.23722 
7 C5- C8 PLGA 1 Single 1.55092 
8 C6-09 PLGA 2 Double 1.23615 
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No. Name Parellt Order ~ Lea~{A) 
9 OJ- Hl PLGA 1 Single 1.05003 
10 C2-H2 PLGA 1 Single 1.09 
11 C2-H3 PLGA I Single 1.09 
12 C5 -H4 PLGA I Single 1.09 
13 C6-H5 PLGA I Single 1.09 
I4 C8- H6 PLGA I Single 1.08996 
15 C8-H7 PLGA 1 Single 1.09003 
16 C8- H8 PLGA I Single I.09003 
The PLGA structure shows the total measurement of 16 bond length with average 
bond length of 1.249333 A. 
Table 4.4 Basic properties of PLGA. 
Properties 




Exact Molecular Weight 
Net Fonnal Charge 
4.1.1.3 Hyaluronic acid (HA) 
PLGA 
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C5 H8 05 








Figure 4.3 Molecular modeling ofHA (with atom number). 
The molecular structure of HA contains nitrogen atom which indicates in blue color 
of modeling in Fig. 4.3. Detail bond length between atoms of HA and its basic 
properties are shown in Table 4.5 and 4.6, respectively. 
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Table 4.5 Bond and bond length of HA. 
No. Name Parent Order Type Len!!th (A) 
I C1-C2 Hyaluronic Acid 1 . Single 1.59635 
2 C2-C3 Hyaluronic Acid 1 Single 1.4931 
3 C3-C4 Hyaluronic Acid 1 Single 1.59474 
4 C4-05 Hyaluronic Acid 1 Single 1.48098 
5 05-C6 Hyaluronic Acid 1 Single 1.38242 
6 C6- C1 Hyaluronic Acid I Single 1.55595 
7 C6-C7 Hyaluronic Acid I Single 1.50029 
8 C7-08 Hyaluronic Acid 2 Double 1.23601 
9 C7-09 Hyaluronic Acid I Single 1.39077 
10 Cl- 010 Hyaluronic Acid 1 Single 1.4566 
11 010-C11 Hyaluronic Acid I Single 1.43783 
12 C2 -012 Hyaluronic Acid I Single 1.42998 
13 C3 -013 Hyaluronic Acid 1 Single 1.42868 
14 C4-014 Hyaluronic Acid I Single 1.45673 
15 014- C15 Hyaluronic Acid I Single 1.45659 
16 Cl5- C16 Hyaluronic Acid 1 Single 1.49247 
17 Cl6- Cl7 Hyaluronic Acid 1 Single 1.60289 
18 C17- 018 Hyaluronic Acid 1 Single 1.4804 
19 018- Cl9 Hyaluronic Acid I Single 1.37854 
20 C19- C20 Hyaluronic Acid I Single 1.56016 
21 C20- C15 Hyaluronic Acid I Single 1.57294 
22 C20- 021 Hyaluronic Acid I Single 1.42935 
23 C19- C22 Hyaluronic Acid I Single 1.53752 
24 C22-023 Hyaluronic Acid I Single 1.42903 
25 C17 -024 Hyaluronic Acid I Single 1.43032 
26 024- C25 Hyaluronic Acid I Single 1.43136 
27 C16-N26 Hyaluronic Acid 1 Single 1.45817 
28 N26 -C27 Hyaluronic Acid I Single 1.34361 
29 C27 -C28 Hyaluronic Acid 1 Single 1.49999 
30 C27 -029 Hyaluronic Acid 2 Double 1.23771 
31 Cl-HI Hyaluronic Acid 1 Single 1.09 
32 C2-H2 Hyaluronic Acid 1 Single 1.09 
33 C3-H3 Hyaluronic Acid I Single 1.09 
34 C4-H4 Hyaluronic Acid I Single 1.09 
35 C6-H5 Hyaluronic Acid I Single 1.09 
36 09-H6 Hyaluronic Acid I Single 1.05003 
37 C11-H7 Hyaluronic Acid 1 Single 1.08996 
38 Cll- H8 Hyaluronic Acid 1 Single 1.09003 
39 C11-H9 Hyaluronic Acid I Single 1.09003 
40 012-HIO Hyaluronic Acid I Single 1.05003 
41 013 -Hll Hyaluronic Acid 1 Single 1.05003 
42 Cl5- H12 Hyaluronic Acid 1 Single 1.09 
43 C16- Hl3 Hyaluronic Acid I Single 1.09 
44 Cl7- H14 Hyaluronic Acid I Single 1.09 
45 C19- H15 Hyaluronic Acid 1 Single 1.09 
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No. Name Pareat Order J)'pe ,,.. .... (A) 
46 C20- Hl6 Hyaluronic Acid I Single 1.09 
47 021- Hl7 Hyaluronic Acid I Single 1.05003 
48 C22- Hl8 Hyaluronic Acid I Single 1.09 
49 C22- Hl9 Hyaluronic Acid I Single 1.09 
50 023- H20 Hyaluronic Acid I Single 1.05003 
51 C25- H21 Hyaluronic Acid 1 Single 1.08996 
52 C25- H22 Hyaluronic Acid l Single 1.09003 
53 C25- H23 Hyaluronic Acid l Single 1.09003 
54 N26- H24 Hyaluronic Acid I Single 1.07 
55 C28 -H25 Hyaluronic Acid 1 Single 1.08996 
56 C28- H26 Hyaluronic Acid I Single 1.09003 
57 C28- H27 Hyaluronic Acid I Single 1.09003 
The HA structure shows the total measurement of 57 bond length with average bond 
length of 1.280556 A. 
Table 4.6 Basic properties of HA. 
Properties HA 
Number of Atoms 56 
Molecular Formula Cl6 H27 012 NI 
Molecular Composition C: 0.452, H: 0.064, 0 : 0.451, N: 0.033 
Molecular Weight 425.399 
Exact Molecular Weight 425.153 
Net Formal Charge 0 
Since some specific HA receptors (CD44) are overexpressed in various malignant 
cell types, linking an antitumor drug to HA might improve targeting to cancerous 
cells and overcome the problem of low drug hydrosolubility (Leonelli et al., 2008). 
4.1.1.4 PEG-bis amine 
Figure 4.4 Molecular modeling ofPEG-bis amine (with atom number). 
The molecular structure of PEG-bis amine contains carbon, hydrogen, oxygen and 
nitrogen atom which indicates in dark grey, light grey, red and blue color 
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respectively of modeling in Fig. 4.4. Detail bond length between atoms of PEG-bis 
amine and its basic properties are shown in Table 4. 7 and 4.8, respectively. 
Table 4. 7 Bond and bond length of PEG-bis amine. 
No. Name · Parent Order Type Lentrth 
1 Nl-C2 Poly( ethylene glycol) bis( amine) I Single 1.46616 
2 C2-C3 Poly( ethylene glycol) bis(amine) 1 Single 1.53352 
3 C3-04 Poly( ethylene glycol) bis(amine) I Single 1.42302 
4 04-C5 Poly( ethylene glycol) bis(amine) 1 Single 1.42302 
5 C5-C6 Poly( ethylene glycol) bis( amine) 1 Single 1.53352 
6 C6-N7 Poly( ethylene glycol) bis( amine) I Single 1.46616 
7 N1- HI Poly( ethylene glycol) bis(amine) I Single 1.02949 
8 N1-H2 Poly( ethylene glycol) bis(amine) I Single 1.02949 
9 C2-H3 Poly( ethylene glycol) bis(amine) 1 Single 1.09939 
10 C2-H4 Poly( ethylene glycol) bis( amine) I Single 1.09939 
11 C3 -H5 Poly( ethylene glycol) bis(amine) I Single 1.09913 
12 C3 -H6 Poly( ethylene glycol) bis(amine) I Single 1.09913 
13 C5-H7 Poly( ethylene glycol) bis(amine) I Single 1.09913 
14 C5 -H8 Poly( ethylene glycol) bis( amine) I Single 1.09913 
15 C6-H9 Poly( ethylene glycol) bis(amine) I Single 1.09939 
16 C6-HIO Poly( ethylene glycol) bis(amine) I Single 1.09939 
17 N7- HII Poly( ethylene glycol) bis( amine) I Single 1.02949 
18 N7 -Hl2 Poly( ethylene glycol) bis(amine) I Single 1.02949 
The PEG-bis amine structure shows the total measurement of 18 bond length with 
average bond length of 1.208747 A. 
Table 4.8 Basic properties of PEG-bis amine. 
Properties PEG-bis amine 
Number of Atoms 19 
Molecular Formula C4H1201 N2 
Molecular Composition C: 0.461, H: 0.116, 0: 0.154, N: 0.269 
Molecular Weight 104.154 
Exact Molecular Weight 104.095 
Net Formal Charge 0 
26 
4.1.2 Multi-molecular Modeling 
4.1.2.1 PLGA-HA 
Figure 4.5 Molecular modeling of PLGA-HA conjugate (with atom number). 
The PLGA-HA conjugate contains only one of each molecule as illustrated in Fig. 
4.5 whereas PLGA is in stick representation. PLGA acts as a drug carrier while HA 
is the tumor-specific targeting vehicle to interact with CD44 receptor at tumor cell. 
Table 4.9 shows PLGA-HA bond length while Table 4.10 shows its basic properties. 
Table 4.9 Bond and bond length ofPLGA-HA conjugate. 
No. NaiBe Pareat Order Type ~ 
I 01 -C2 PLGA I Single 1.45449 
2 C2-C3 PLGA I Single 1.4912 
3 C3 -04 PLGA 1 Single 1.38889 
4 04-C5 PLGA I Single 1.42627 
5 C5-C6 PLGA I Sin~le 1.49706 
6 C2-C7 PLGA I Single 1.55577 
7 C3 -08 PLGA 2 Double 1.23613 
8 C6-09 PLGA 2 Double 1.23605 
9 C6- 010 PLGA I Single 1.38972 
10 C2- H2 PLGA I Single 1.09863 
II C5- H3 PLGA I Single 1.10014 
12 C5- H4 PLGA I Single 1.09925 
13 C7- H5 PLGA 1 Single 1.09859 
14 C7 -H6 PLGA I Single 1.09911 
15 C7- H7 PLGA I Single 1.09946 
16 010- H8 PLGA I Single 0.989376 
17 OI-Cl9 HA I Single 1.40638 
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No. Name Parent ·order Type Leneth (..\) 
I8 CI9- C22 HA I Single 1.5023 
I9 C22 -H6 HA I Single 1.09869 
20 C22 -H7 HA I Single 1.09861 
2I Cl9- 025 HA 2 Double 1.23636 
22 CI9-H9 HA I Single 1.05814 
23 025 -HIO HA I Single 0.956449 
24 025 -Hll HA I Single 0.955898 
25 025 -H12 HA I Single 0.957543 
26 CI-C2 HA I Single 1.65527 
27 C2-C3 HA I Single 1.43775 
28 C3-C4 HA I Single 1.64816 
29 C4-05 HA I Sin11.le 1.5115 
30 05-C6 HA I Sin11.le 1.3I797 
3I C6-CI HA I Single 1.58321 
32 C6-C7 HA I Single 1.48369 
33 C7 -08 HA 2 Double 1.23591 
34 C7 -09 HA I Single 1.3794 
35 Cl- 010 HA I Single 1.45766 
36 010-Cll HA I Single 1.44215 
37 C2-012 HA I Single 1.4279 
38 C3 -013 HA I Single 1.42559 
39 C4 -OI4 HA I Single 1.455 
40 014- CIS HA I Single 1.462 
41 CIS- Cl6 HA I Single 1.45104 
42 Cl6- CI7 HA I Single 1.66827 
43 Cl7-018 HA I Single 1.52245 
44 018- Cl9 HA I Single 1.3I8I8 
45 Cl9- C20 HA I Single 1.57756 
46 C20- CIS HA I Single 1.6257 
47 C20 -021 HA I Single 1.4359 
48 CI9- C22 HA I Single 1.52833 
49 C22 -023 HA I Single 1.42626 
50 Cl7- 024 HA I Single 1.42995 
51 024-C25 HA I Single 1.42988 
52 Cl6- N26 HA I Single 1.4666 
53 N26 -C27 HA I Single 1.34458 
54 C27 -C28 HA I Sin11.le 1.4954 
55 C27 -029 HA 2 Double 1.23692 
56 Cl- HI HA I Single 1.09839 
57 C2-H2 HA I Single 1.09906 
58 C3 -H3 HA I Single 1.10303 
59 C4-H4 HA I Single 1.098I7 
60 C6-H5 HA I Single 1.10296 
61 Cli-H7 HA I Single 1.0989 
62 Cli-H8 HA I Single 1.08647 
63 Cli-H9 HA 1 Single 1.09904 
64 012 -HJO HA I Single 0.979453 
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No. Name Parent Order T~ Leneth(A) 
65 013-Hll HA I Single 0.988772 
66 Cl5- Hl2 HA I Single 1.09629 
67 Cl6- Hl3 HA I Single 1.10109 
68 Cl7- Hl4 HA I Single 1.09631 
69 Cl9 -Hl5 HA I Single 1.10263 
70 C20-Hl6 HA I Single 1.09749 
71 021- Hl7 HA I Single 0.986586 
72 C22-H18 HA I Single 1.09779 
73 C22-Hl9 HA I Single 1.09873 
74 023 -H20 HA I Single 0.988731 
75 C25 -H21 HA I Single 1.09904 
76 C25- H22 HA I Single 1.09957 
77 C25- H23 HA I Single 1.09928 
78 N26-H24 HA I Single 0.993172 
79 C28 -H25 HA I Single 1.09945 
80 C28- H26 HA I Single 1.09947 
81 C28 -H27 HA I Single 1.09947 
82 09-C22 HA I Single 1.41757 
The PLGA-HA conjugate shows the total measurement of 82 bond length with 
average bond length of 1.266312 A. 
Table 4.10 Basic properties ofPLGA-HA conjugate. 
. Properties PLGA-HA roniu2ate 
Number of Atoms 81 
Molecular Formula C23 H39 018 Nl 
Molecular Composition C: 0.447, H: 0.064, 0: 0.466, N: 0.023 
Molecular Weight 617.572 
Exact Molecular Weight 617.217 
Net Formal Charge 0 
4.1.2.2 Curcumiu-HA 
One molecule of HA conjugated with one molecule of curcumin appearing in stick 
representation as illustrated in Fig. 4.5. Table 4.11 shows the bond length of this 
conjugate structure and Table 4.12 shows its basic properties. 
In a study shows another important aspect ofHA-Curcumin conjugate micelles is the 
protection of curcumin from degradation at physiological pH. Almost 90% of 
curcumin degradation occur within 30 min, but the conjugation has resulted in 
minimal change in the adsorption maximum even after 8 hr of incubation at 3TC 
(Manju & Sreenivasan, 20 II). 
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Figure 4.6 Molecular modeling of Curcumin-HA conjugate (with atom number). 
Table 4.11 Bond and bond length of Curcumin-HA conjugate. 
No. Name Parat Order Type Lelaa6(A) 
1 C1 -C2 Curcumin 2 Double 1.32394 
2 C2-C3 Curcumin I Single 1.43878 
3 C3 -C4 Curcumin 2 Double 1.32559 
4 C4- C5 Curcumin I Single 1.48737 
5 C5 -C6 Curcumin 2 Double 1.36542 
6 C6-CI Curcumin I Single 1.47133 
7 C6-08 Curcurnin I Single 1.46237 
8 C9- CIO Curcumin 2 Double 1.33506 
9 CIO-Cll Curcumin I Single 1.45425 
10 C11-C12 Curcumin I Single 1.49463 
It C12- CJ3 Curcurnin I Single 1.49428 
12 Cl3- Cl4 Curcumin I Single 1.4547 
13 C14- Cl5 Curcumin 2 Double 1.33452 
14 C15-CI6 Curcumin I Single 1.48586 
15 C2-C9 Curcumin I Single 1.48015 
16 Cll-017 Curcumin 2 Double 1.23584 
17 Cl3-018 Curcurnin 2 Double 1.23586 
18 C19- C20 Curcumin 2 Double 1.33284 
19 C20- C21 Curcurnin 1 Single 1.55537 
20 C21- C22 Curcurnin 2 Double 1.33199 
21 C22- C23 Curcurnin 1 Single 1.45335 
22 CI6-Cl9 Curcumin I Single 1.4565 
23 Cl6- C23 Curcurnin 2 Double 1.33299 
24 C20 -024 Curcurnin I Single 1.45357 
25 C21 -025 Curcumin I Single 1.42359 
26 024 - C26 Curcumin 1 Single 1.41593 
27 08- C27 Curcurnin 1 Single 1.43541 
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No. Name .· Parent Order Type· Len!rth (A) 
28 Cl-Hl Cure urn in 1 Single 1.06019 
29 C3-H2 Curcumin 1 Single 1.05252 
30 C4-H3 Curcumin 1 Single 1.02923 
31 C9-H5 Curcumin 1 Single 1.06019 
32 C10-H6 Curcumin 1 Single 1.05784 
33 C12-H7 Curcumin 1 Single 1.09886 
34 C12-H8 Curcumin 1 Single 1.10038 
35 C14-H9 Curcumin 1 Single 1.0563 
36 CI5-H10 Curcumin I Single 1.0602 
37 C19- Hll Curcumin 1 Single 1.06021 
38 C22 -Hl2 Curcumin 1 Single 1.06026 
39 C23 -H13 Curcumin 1 Single 1.05705 
40 025 -H14 Curcumin 1 Single 0.941093 
41 C26- HIS Curcumin 1 Single 1.09934 
42 C26-H16 Cure urn in 1 Single 1.09958 
43 C26-H17 Curcumin 1 Single 1.09959 
44 C27- HIS Cure urn in 1 Single 1.09924 
45 C27 -H19 Cure urn in 1 Single 1.09991 
46 C27 -H20 Cure urn in 1 Single 1.09995 
47 Cl-C2 HA 1 Single 1.64311 
48 C2-C3 HA 1 Single 1.43863 
49 C3-C4 HA 1 Single 1.63816 
50 C4-05 HA 1 Single 1.52075 
51 05 -C6 HA 1 Single 1.33557 
52 C6-Cl HA 1 Single 1.58622 
53 C6-C7 HA 1 Single 1.52527 
54 C7-08 HA 2 Double 1.23583 
55 C7-09 HA 1 Single 1.46687 
56 Cl- 010 HA 1 Single 1.45904 
57 010- Cll HA 1 Single 1.44321 
58 C2- 012 HA 1 Single 1.42779 
59 C3 -013 HA 1 Single 1.42528 
60 C4-014 HA 1 Single 1.43113 
61 014- Cl5 HA 1 Single 1.46174 
62 CIS- Cl6 HA 1 Single 1.47818 
63 C16-C17 HA 1 Single 1.67568 
64 C17- 018 HA 1 Single 1.52053 
65 018- C19 HA 1 Single 1.31474 
66 C19- C20 HA 1 Single 1.57355 
67 C20- CIS HA 1 Single 1.61159 
68 C20-021 HA 1 Single 1.43504 
69 C19- C22 HA 1 Single 1.52861 
70 C22-023 HA 1 Single 1.42564 
71 C17 -024 HA 1 Single 1.43039 
72 024-C25 HA I Single 1.43002 
73 C16-N26 HA 1 Single 1.47832 
74 N26-C27 HA 1 Single 1.34839 
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No. Name ·Parent Order TVDe Leneth(A) 
75 C27 -C28 HA I Sinl!;le 1.49404 
76 C27 -029 HA 2 Double 1.23677 
77 CI-HI HA I Single 1.09839 
78 C2-H2 HA I Sinl!;le 1.09929 
79 C3-H3 HA I Sinl!;le 1.10267 
80 C4-H4 HA I Sin!!;le 1.09536 
81 C6-H5 HA I Sin!!;le 1.09457 
82 Cll-H7 HA I Sinl!;le 1.09889 
83 Cll-H8 HA I Sinl!;le 1.08652 
84 Cll- H9 HA I Sinl!;le 1.09909 
85 012- HIO HA I Sinl!;le 0.97984I 
86 013-Hil HA I Single 0.988798 
87 CIS- Hl2 HA I Sinl!;le 1.09834 
88 Cl6- Hl3 HA I Sinl!:le 1.10064 
89 Cl7- Hl4 HA I Sinl!;le 1.09307 
90 Cl9- HIS HA I Sinl!;le 1.10252 
9I C20- Hl6 HA I Sinl!;le 1.09I09 
92 021 - Hl7 HA I Sinl!:le 0.987153 
93 C22- HIS HA I Sinl!;le 1.10075 
94 C22- Hl9 HA I Sinl!;le 1.09852 
95 023 -H20 HA I Sinl!;le 0.988783 
96 C25- H2I HA I Sinl!;le 1.09902 
97 C25 -H22 HA I Single 1.09959 
98 C25 -H23 HA I Sinl!;le 1.09926 
99 N26 -H24 HA I Sinl!;le 0.992856 
IOO C28 -H25 HA I Sinl!;le 1.09925 
IOI C28 -H26 HA I Single 1.10017 
102 C28 -H27 HA I Sinl!;le 1.09939 
I03 09-C5 HA I Sinl!;le 1.46764 
The Curcumin-HA conjugate shows the total measurement of I03 bond length with 
average bond length of 1.280048 A. HA-Curcumin conjugates is amphipilic in nature 
containing both hydrophobic core by curcumin and the hydrophilic HA protruding 
outwardly and form shell layer (Gul-e-Saba, et al., 20II). 




Number of Atoms 100 
Molecular Formula C37 H45 017 Nl 
Molecular Composition C: 0.573, H: 0.058, 0:0.351, N: 0.018 
Molecular Weight 775.774 
Exact Molecular Weight 775.269 





Figure 4.7 Molecular modeling ofPLGA-PEG-HA conjugate (with atom number). 
One molecule of HA conjugated with one molecule of PEG-bis amine as a spacer 
appearing in stick representation and one molecule of PLGA as illustrated in Fig. 
4.7. This conjugated structure has been modeled from skeletal structure in Fig.3.2. 
Table 4.13 shows the bond length of this conjugate structure and Table 4.14 shows 
its basic properties. 
Table 4.13 Bond and bond length ofPLGA-PEG-HA conjugate. 
No. Name Pareat Order Type Lea~ 
1 CI- C2 HA I Single 1.65421 
2 C2-C3 HA I Single 1.43798 
3 C3 -C4 HA 1 Single 1.64219 
4 C4-05 HA I Sin__gle 1.51794 
5 05 -C6 HA I Sin__gle 1.32966 
6 C6- CI HA I Single 1.58803 
7 C6-C7 HA I Single 1.54045 
8 C7 -08 HA 2 Double 1.23577 
9 Cl-010 HA I Single 1.45877 
10 010-CII HA 1 Single 1.44341 
II C2- 012 HA I Single 1.4279 
12 C3- 013 HA I Single 1.42562 
13 C4- 014 HA I Single 1.45506 
14 014-CIS HA I Single 1.46159 
15 CIS- CI6 HA I Single 1.45083 
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No. Name Parent Order· Type . Length(A) 
16 Cl6-CI7 HA I Single 1.66793 
17 Cl7-018 HA I Single 1.52218 
18 018- C19 HA I Single 1.31802 
19 Cl9- C20 HA I Single 1.57516 
20 C20- CIS HA I Single 1.61966 
21 C20-021 HA I Single 1.43594 
22 Cl9- C22 HA I Single 1.53067 
23 C22-023 HA 1 Sin~le 1.42623 
24 C17 -024 HA 1 Single 1.42983 
25 024-C25 HA I Single 1.42979 
26 Cl6- N26 HA I Single 1.46651 
27 N26-C27 HA 1 Single 1.34448 
28 C27 -C28 HA 1 Single 1.49547 
29 C27 -029 HA 2 Double 1.2369 
30 Cl- HI HA I Single 1.0983 
31 C2-H2 HA I Single 1.09903 
32 C3-H3 HA I Single 1.10268 
33 C4-H4 HA 1 Single 1.09819 
34 C6-H5 HA 1 Single 1.10187 
35 Cll-H7 HA I Single 1.09891 
36 Cll -H8 HA 1 Single 1.08611 
37 Cll-H9 HA I Single 1.099 
38 012- HIO HA I Single 0.979109 
39 013- HII HA I Single 0.988776 
40 CIS- Hl2 HA I Single 1.09638 
41 Cl6-Hl3 HA 1 Single 1.10112 
42 C17-HI4 HA I Single 1.09635 
43 Cl9- Hl5 HA I Single 1.10271 
44 C20- Hl6 HA I Single 1.09509 
45 021-H17 HA 1 Single 0.986539 
46 C22-H18 HA I Single 1.10032 
47 C22-Hl9 HA I Single 1.09901 
48 023 -H20 HA I Single 0.989312 
49 C25 -H21 HA I Single 1.09903 
50 C25- H22 HA I Single 1.09954 
51 C25 -H23 HA I Single 1.0993 
52 N26 -H24 HA I Single 0.993187 
53 C28-H25 HA I Single 1.09942 
54 C28-H26 HA I Single 1.09951 
55 C28- H27 HA 1 Single 1.09947 
56 NI-C7 PEG-HA I Single 1.34936 
57 N1-C2 PEG-bis amine 1 Single 1.43977 
58 C2-C3 PEG-bis amine I Single 1.53534 
59 C3-04 PEG-bis amine 1 Single 1.42819 
60 04-C5 PEG-bis amine 1 Single 1.42779 
61 C5 -C6 PEG-bis amine I Single 1.53802 
62 C6-N7 PEG-bis amine I Single 1.43419 
34 
No. Name ·Parent Order Type Lemrth (A) 
63 N7-C8 PEG-bis amine I Single 1.39519 
64 C8-09 PEG-bis amine 2 Double 1.23641 
65 Nl-H40 PEG-bis amine I Single 1.07 
66 C2 -H41 PEG-bis amine I Single 1.09 
67 C2- H42 PEG-bis amine I Single 1.09 
68 C3 -H43 PEG-bis amine I Single 1.09 
69 C3 -H44 PEG-bis amine I Single 1.09 
70 C5 -H45 PEG-bis amine I Single 1.09 
71 C5 -H46 PEG-bis amine I Single 1.09 
72 C6- H47 PEG-bis amine I Single 1.09 
73 C6- H48 PEG-bis amine I Single 1.09 
74 N7-H49 PEG-bis amine I Single 1.07 
75 C8 -01 PLGA-PEG I Single 1.39224 
76 Ol-C2 PLGA I Single 1.43024 
77 C2-C3 PLGA I Single 1.49798 
78 C3 -04 PLGA I Single 1.39185 
79 04-C5 PLGA I Single 1.42868 
80 C5 -C6 PLGA I Single 1.49864 
81 C6-07 PLGA I Single 1.4095 
82 07-C8 PLGA I Single 1.44536 
83 C8-C9 PLGA I Single 1.49838 
84 C9-0IO PLGA I Single 1.40994 
85 010- Cll PLGA I Single 1.44508 
86 Cll - Cl2 PLGA I Single 1.50032 
87 C3 -013 PLGA 2 Double 1.23636 
88 C6-014 PLGA 2 Double 1.23702 
89 Cl2- 015 PLGA 2 Double 1.23615 
90 Cll- Cl6 PLGA I Single 1.55065 
91 C8-Cl7 PLGA I Single 1.55089 
92 C9-018 PLGA 2 Double 1.23706 
93 C2-H27 PLGA I Single 1.09 
94 C2-H28 PLGA I Single 1.09 
95 C5 -H29 PLGA I Single 1.09 
96 C5 -H30 PLGA I Single 1.09 
97 C8- H31 PLGA I Single 1.09 
98 Cll-H32 PLGA I Single 1.09 
99 Cl2- H33 PLGA I Single 1.09 
100 Cl6- H34 PLGA I Single 1.08996 
101 Cl6- H35 PLGA I Single 1.09003 
102 Cl6-H36 PLGA I Single 1.09003 
103 Cl7-H37 PLGA I Single 1.08995 
104 Cl7- H38 PLGA I Single 1.09003 
105 Cl7- H39 PLGA I Single 1.09003 
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The PLGA-PEG-HA conjugate shows the total measurement of 105 bond length 
with average bond length of 1.274163 A. Considering the bond no. 56 it indicates the 
bond between N7-C7 atoms where the conjugation between PEG and HA occurred 
and also at the bond no.75 indicates where the conjugation between PEG and PLGA 
occurred with C8-0 I atoms. 
Table 4.14 Basic properties ofPLGA-PEG-HA conjugate. 
Properties PLGA-PEG-HA eo~~jqate 
Number of Atoms 104 
Molecular Formula C31 H49 021 N3 
Molecular Composition C: 0.466, H: 0.062, 0:0.420, N: 0.053 
Molecular Weight 799.754 
Exact Molecular Weight 799.286 
Net Formal Charge 0 
The PLGA-PEG-HA conjugates can successfully prepared via reaction of one of the 
amino groups of PEG-bis amine with carboxylic group of HA and reacting second 
free amino group with PLGA (Fig. 3.2) (Yadav, et al., 2010). This conjugate 
molecule will be used for preparation of nanoparticles as a drug carrier. 
4.1.2.4 Curcumio-PLGA-PEG-HA 
Figure 4.8 Molecular modeling of Curcumin-PLGA-PEG-HA nanoparticle. 
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Fig 4.8 shows the PLGA-PEG-HA nanoparticle with one molecule of curcumin as 
anticancer agent inside the hydrophobic core of spherical shape whereas at the 
surface of nanoparticle contains hydrophilic micelles of 15 PLGA-PEG-HA 
molecules. The basic process of synthesizing this nanoparticles is, first is to 
synthesize the empty nano-conjugates ofPLGA-PEG-HA. Secondly, the curcumin is 
put into it by preparing the curcumin solution formed in water miscible organic 
solvents and during the synthesis of curcumin containing in nanoparticles, the 
streams of polymer (PLGA-PEG-HA) will collide with other stream of curcumin. 
Third, the hydrophobic curcumin and conjugate polymers will precipitate out of 
solution in an attempt to avoid the water molecules and finally the polymers 
immediately self-assemble onto the curcumin to form a coating with the hydrophobic 
portion attached to the nanoparticle core containing curcumin and the hydrophilic 
portion containing HA stretching out into the water solution. 
Since the major roadblocks in curcumin development as a therapeutic for cancer is 
its poor water solubility and limited bioavailability therefore by using biodegradable 
nanoparticle like PLGA-PEG would exhibit enhanced cellular uptake and increase its 
bioavailability (Anand, et al., 2009). It is also been reported that grafting of PEG to 
the surface of nanoparticle containing PLGA will reduce the interaction between the 
nanoparticles and digestive enzymes, increases uptake of the encapsulated drug in 
the bloodstream and lymphatic tissue and also increase its half-life in the blood 
circulation (Dinarvand, et al., 2011 ). Conjugation to HA not only further increases 
the drug solubility but more importantly it enhances the chances to reach the cancer 
site. CD44 is overexpressed in human cancer cells and it is cell membrane-localized 
receptors or HA binding proteins therefore HA can bind to the cell surface via 
interactions with CD44 (Luo, et al., 2009). HA-PEG-PGLA uptake by CD44 
receptor via endocytosis. The main advantage of the conjugation of drug to 
biodegradable polyester like PLGA-PEG is, first to prevent the initial burst and 
control the sustained release of molecules from nanoparticles (Oh, et al., 2007) and 
secondly is drug-polymer conjugates are easily formulated into nanoparticles by 
nano-precipitation method with very high encapsulation efficiency (almost 100%) 
(Anand, et al., 2009). In the study ofYadav, et al. (2010) has concluded that PLGA-
PEG-HA nanoparticles can serve as efficient tools to ferry large doses of anti-cancer 





The three dimensional molecular modeling of the following molecule had been 
successfully developed using Discovery Studio 2.5: Curcumin, PLGA, HA, PEG-bis 
amine, PLGA conjugated HA, Curcumin conjugated HA, PLGA-PEG-HA 
conjugates and Curcumin-PLGA-PEG-HA nanoparticles. HA conjugates with 
nanoparticles molecules have high potential as targeted delivery vehicle to transport 
the anticancer agent to cancer cells and it also improves the stability, bioavailability 
of anticancer hydrophobic drug as compared to free curcumin. These molecular 
modeling might be further used as one of the references regarding the drug 
development method or molecular modeling study. Furthermore the nanoparticle 
model can also be modeled for CD44 target and this could possibly pave the way for 
rational design of target-specific drug delivery. 
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